Pfizer eyeing biotechs, others for next billion-dollar drugs

07/2/2006 | Detroit Free Press

Pfizer says it is looking at biotechs as well as other drugmakers as part of a $17 billion budget to buy some of the next billion-dollar drugs over the next two years. The firm plans to get access to the drugs through acquisitions or product licenses, focusing on deals that cost between $1 billion and $4 billion, according to the firm's global research president.

View Full Article in:

Detroit Free Press

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL